Allergan to Buy Kythera Biopharmaceuticals for $2.1B

Features Dow Jones Newswires

Botox-maker Allergan Plc said it would buy Kythera Biopharmaceuticals Inc in a cash-and-stock deal valued at about $2.1 billion, to expand its line of cosmetic treatments.

Continue Reading Below

The offer price of $75 per share represents a premium of 23.5 percent to Kythera's Tuesday close.

Kythera's shares rose 22.7 percent to $74.50 in premarket trade on Wednesday, just shy of Allergan's offer price.

Buying Kythera will give Allergan access to Kybella, the first and only approved non-surgical treatment to reduce fat under the chin, the companies said.

The equity value of the deal is about $1.94 billion, based on 25.8 million Kythera shares outstanding as of April 6, according to Thomson Reuters calculations.

The deal is Allergan's first multi-billion acquisition since it was bought by Actavis Plc for $66 billion. Ireland-based Actavis, which announced the Allergan deal in November, adopted the Botox-maker's name on June 15.

Continue Reading Below

Allergan said it expected the deal to begin adding to earning per share after 2016.

J.P. Morgan is financial adviser to Allergan and Covington & Burling LLP is the company's lead legal counsel. Goldman Sachs is Kythera's financial adviser. (Reporting by Vidya L Nathan in Bengaluru, Editing by Simon Jennings)